NVO’s Ryzodeg Approved in Japan – Analyst Blog

By | December 29, 2012
0 Comment

Denmark based Novo Nordisk ( NVO ) recently announced that it has received approval in Japan for its diabetes treatment, Ryzodeg (insulin degludec/insulin aspart). Ryzodeg was submitted

Continued here:
NVO’s Ryzodeg Approved in Japan – Analyst Blog

Related posts:

  1. Watson’s Generic Product Approved – Analyst Blog
  2. Novo Nordisk Offers Steady Gains To Go With Dividend
  3. Roche’s Tamiflu Label Expanded – Analyst Blog
  4. Thoratec Wins Approval in Japan – Analyst Blog